1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-06-30 am EDT
17.50 HKD   +6.71%
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use
CI
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

04/12/2022 | 06:51am EDT

Venus Medtech (Hangzhou) Inc. announced that Venus-Neo, a new generation of expandable bioprosthetic dry tissue valve developed by the Company, has successfully completed the first clinical application of First-in-Man (FIM) trials in the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. As the Company's first surgical bioprosthetic valve, Venus-Neo features a supra-annular design with bovine pericardium tissue as the valve leaflet. With optimized valve design and unique anti-calcification dry tissue technology (Venus-Endura), Venus-Neo can be stored in a fluid-free environment without aldehyde residue, offering enhanced safety and facilitating clinical application, storage and transportation. As China's aging population increases, aortic valve disease has become one of the most common valvular heart diseases, and surgical aortic valve replacement (SAVR) is currently the standard treatment for the aortic stenosis and aortic regurgitation, with strong long-term clinical evidence. However, the high risk associated with reoperation after bioprosthetic valve deterioration cannot be ignored. Valve-in-valve procedure is increasingly being used in the treatment of surgical bioprosthetic valve deterioration, and Venus-Neo's expansion zone provides a better choice for patients who may require the valve-in-valve treatment in the future. This is another new generation of dry tissue valve product with special design from the Company that has entered clinical studies after Venus-Vitae and Venus-PowerX, marking a milestone for the Company to achieve a full layout of aortic valve disease solutions while enhancing the durability of bioprosthetic valves, consolidating the Company's position as a leader in the treatment of valvular heart diseases in China. The Board looks forward that the Company will complete Venus-Neo's clinical studies rapidly, by leveraging its technical advantage and continue its layout of new generation innovative products so as to benefit valvular heart disease patients worldwide.


© S&P Capital IQ 2022
All news about VENUS MEDTECH (HANGZHOU) INC.
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Com..
CI
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
CI
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
MT
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
AQ
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
CI
03/18Venus Medtech Inc. Appoints Shakeel Osman as Senior Vice President of Sales Europe
CI
03/18Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercializ..
AQ
More news
Financials
Sales 2022 657 M 98,1 M 98,1 M
Net income 2022 -305 M -45,6 M -45,6 M
Net cash 2022 2 508 M 374 M 374 M
P/E ratio 2022 -24,0x
Yield 2022 -
Capitalization 6 542 M 977 M 977 M
EV / Sales 2022 6,14x
EV / Sales 2023 4,23x
Nbr of Employees 905
Free-Float 79,7%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 14,94 CNY
Average target price 21,69 CNY
Spread / Average Target 45,2%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Haiyue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VENUS MEDTECH (HANGZHOU) INC.-40.88%977
STRYKER CORPORATION-25.61%75 415
SMITH & NEPHEW PLC-11.25%12 241
INSPIRE MEDICAL SYSTEMS, INC.-20.60%5 181
AXONICS, INC.1.20%2 715
DOUBLE MEDICAL TECHNOLOGY INC.-22.68%2 398